Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxapram versus placebo in preterm newborns with apnea of prematurity
NL-OMON60739Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in apnea of prematurity (AOP) comparing Doxapram with Placebo (2 arms). Primary endpoints: Composite of death or severe disability, Death and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
doxapram
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on NL-OMON60739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60739.